Blocking the Signal: Interrupting Inflammatory Signaling in Atopic Dermatitis
QUBES · 23.08.2026
DOI: 10.25334/2kn6-fm79 ↗Kurz gefasst
Fachartikel in der Zeitschrift QUBES, erschienen am 23.08.2026. Verfasst von Youngjoo Kim.
Abstract (Originalsprache)
Learning Objectives Explain how monoclonal antibodies can be used as therapeutic agents to treat disease. Describe the molecular mechanism by which an antibody inhibitor disrupts interleukin signaling pathways. Analyze the three-dimensional structures of IL-4 bound to the IL-4 receptor and dupilumab bound to the IL-4 receptor. Identify and compare the intermolecular forces involved in IL-4–IL-4 receptor interactions versus dupilumab–IL-4 receptor interactions.
Schlagwörter
Zitieren
APA
Kim, Y. (2026). Blocking the Signal: Interrupting Inflammatory Signaling in Atopic Dermatitis. QUBES. https://doi.org/10.25334/2kn6-fm79
Vancouver
Kim Y. Blocking the Signal: Interrupting Inflammatory Signaling in Atopic Dermatitis. QUBES. 2026. doi:10.25334/2kn6-fm79
BibTeX
@article{Kim2026,
author = {Kim, Youngjoo},
title = {Blocking the Signal: Interrupting Inflammatory Signaling in Atopic Dermatitis},
journal = {QUBES},
year = {2026},
doi = {10.25334/2kn6-fm79}
}
EUVIMED